Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
BridgeBio Pharma
Biotech
BridgeBio's calcium deficiency candidate scores phase 3 win
Encaleret aced a phase 3 trial, restoring healthy calcium levels in the blood and urine and teeing up an FDA filing next year.
Darren Incorvaia
Oct 29, 2025 7:00am
BridgeBio aces phase 3 rare disease test, clearing path to FDA
Oct 27, 2025 7:00am
BridgeBio's cancer spinout backs SPAC as path to Nasdaq
Feb 28, 2025 9:25am
BridgeBio cuts gene therapy budget as clinical data disappoint
Sep 11, 2024 7:50am
BridgeBio’s offshoot GondolaBio launches with $300M
Aug 21, 2024 11:36am
Moderna, Terremoto, MEI Pharma and more—Chutes & Ladders
Jul 26, 2024 8:30am
